What are the benefits and risks of the combination of clopidogrel and aspirin for patients undergoing surgical revascularization for non-ST-elevation acute coronary syndrome?
The benefits of combining clopidogrel and aspirin for patients undergoing surgical revascularization for non-ST-elevation acute coronary syndrome include a reduction in recurrent ischemic events and an improvement in long-term outcomes. However, there are also risks associated with this combination, such as an increased risk of bleeding. These risks were identified in the Clopidogrel in Unstable angina to prevent Recurrent ischemic Events (CURE) Trial, which found that the combination of clopidogrel and aspirin was associated with an increased risk of bleeding compared to aspirin alone.